PEGINTERFERON BETA-1A IMPROVES CLINICAL AND RADIOLOGICAL DISEASE OUTCOMES IN PATIENTS WHO ARE NEWLY DIAGNOSED WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): SUBGROUP ANALYSIS OF ADVANCE

Newsome Scott D.; Arnold Douglas L.; Yun Jang; Meergans Matthias; Naylor Maria L.

首页> 外文期刊>Journal of Neurology, Neurosurgery and Psychiatry >PEGINTERFERON BETA-1A IMPROVES CLINICAL AND RADIOLOGICAL DISEASE OUTCOMES IN PATIENTS WHO ARE NEWLY DIAGNOSED WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): SUBGROUP ANALYSIS OF ADVANCE

【24h】

PEGINTERFERON BETA-1A IMPROVES CLINICAL AND RADIOLOGICAL DISEASE OUTCOMES IN PATIENTS WHO ARE NEWLY DIAGNOSED WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): SUBGROUP ANALYSIS OF ADVANCE

机译：Peginterferonβ1a改善了新诊断的患者的临床和放射性疾病结果，这些患者被重复延迟多发性硬化（RRMS）：亚组分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Neurology, Neurosurgery and Psychiatry》 |2018年第6期|共1页
作者
Newsome Scott D.; Arnold Douglas L.; Yun Jang; Meergans Matthias; Naylor Maria L.;
展开▼
作者单位

Johns Hopkins Univ Sch Med Dept Neurol Baltimore MD 21205 USA;

McGill Univ Montreal Neurol Inst Montreal PQ Canada;

Biogen Cambridge MA USA;

Biogen Zug Switzerland;

Biogen Cambridge MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学;
关键词

相似文献

外文文献
中文文献
专利

1. PEGINTERFERON BETA-1A IMPROVES CLINICAL AND RADIOLOGICAL DISEASE OUTCOMES IN PATIENTS WHO ARE NEWLY DIAGNOSED WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): SUBGROUP ANALYSIS OF ADVANCE [J] . Newsome Scott D., Arnold Douglas L., Yun Jang, Journal of Neurology, Neurosurgery and Psychiatry . 2018,第6期

机译：Peginterferonβ1a改善了新诊断的患者的临床和放射性疾病结果，这些患者被重复延迟多发性硬化（RRMS）：亚组分析
2. BASELINE CHARACTERISTICS AND SAFETY PROFILE OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE FIRST INTERIM ANALYSIS OF THE PEGINTERFERON BETA-1A TREATMENT IN THE PHASE 4 PLEGRIDY OBSERVATIONAL PROGRAM (POP) [J] . Salvetti Marco, Yun Jang, Appiah-Badu David, Journal of Neurology, Neurosurgery and Psychiatry . 2018,第6期

机译：在第4阶段Plegrivy观察程序（POP）中Peginterferonβ1a治疗的第一次临时分析中复制多发性硬化症（RRMS）的患者的基线特征和安全性。
3. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis [J] . Newsome Scott D., Kieseier Bernd C., Arnold Douglas L., Journal of neurology . 2016,第9期

机译：聚乙二醇干扰素β-1aADVANCE试验对复发缓解型多发性硬化症患者进行的2年年复发率的亚组和敏感性分析
4. A machine learning pipeline for multiple sclerosis course detection from clinical scales and patient reported outcomes [C] . Fiorini Samuele, Verri Alessandro, Tacchino Andrea, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2015

机译：用于从临床量表和患者报告的结果进行多发性硬化症课程检测的机器学习管道
5. The Impact of Coping Strategies Exercised by Children and Their Families on Clinical Management, Disease Outcome, and Emotional Well-Being in Children with Newly Diagnosed Inflammatory Bowel Disease [D] . Collins, Derek Alexander. 2019

机译：儿童及其家庭行使的应对策略对临床管理，疾病结果以及新诊断的炎症性肠病患儿的临床管理，疾病结果和情感福祉
6. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial [O] . Douglas L. Arnold, Peter A. Calabresi, Bernd C. Kieseier, 2017

机译：Peginterferon beta-1a改善了MRI测量并增加了复发-缓解型多发性硬化症中无疾病活动证据的患者比例：ADVANCE随机对照试验的2年结果
7. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial [O] . Douglas L. Arnold, Peter A. Calabresi, Bernd C. Kieseier, 2017

机译：Peginterferon beta-1a改善了MRI测量并增加了复发-缓解型多发性硬化症中无疾病活动证据的患者比例：ADVANCE随机对照试验的2年结果

PEGINTERFERON BETA-1A IMPROVES CLINICAL AND RADIOLOGICAL DISEASE OUTCOMES IN PATIENTS WHO ARE NEWLY DIAGNOSED WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): SUBGROUP ANALYSIS OF ADVANCE

著录项

相似文献

相关主题

期刊订阅